Evogene Ltd. (NASDAQ:EVGN) Short Interest Update

Evogene Ltd. (NASDAQ:EVGN) was the target of a significant growth in short interest in February. As of February 15th, there was short interest totalling 16,000 shares, a growth of 22.1% from the January 31st total of 13,100 shares. Based on an average daily volume of 48,600 shares, the short-interest ratio is currently 0.3 days. Currently, 0.3% of the shares of the stock are short sold.

Evogene Trading Up 6.3 %

EVGN opened at $1.41 on Thursday. The firm has a market capitalization of $7.58 million, a PE ratio of -0.32 and a beta of 1.29. Evogene has a twelve month low of $1.20 and a twelve month high of $10.00. The firm’s 50-day moving average price is $1.59 and its 200 day moving average price is $2.09.

Hedge Funds Weigh In On Evogene

A hedge fund recently bought a new stake in Evogene stock. Citadel Advisors LLC bought a new stake in Evogene Ltd. (NASDAQ:EVGN) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 15,891 shares of the biotechnology company’s stock, valued at approximately $30,000. Citadel Advisors LLC owned about 0.30% of Evogene at the end of the most recent reporting period. 10.40% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on shares of Evogene in a research note on Sunday. They set a “sell” rating for the company.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.